Federal Register / Vol. 75, No. 40 / Tuesday, March 2, 2010 / Notices 9423 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Orthopaedic and 

Rehabilitation Devices Panel of the 

Medical Devices Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on March 23, 2010, from 8 a.m. to 

5 p.m. 

Location: Hilton Washington DC 

North/Gaithersburg, Salons A, B, C and 

D, 620 Perry Pkwy., Gaithersburg, MD. 

Contact Person: Tracy Phillips, Center 

for Devices and Radiological Health, 

Food and Drug Administration, 10903 

New Hampshire Ave., Silver Spring, MD 

20993, 301–796–6150, 

Tracy.Phillips@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), code 

3014512521. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: On March 23, 2010, the 

committee will discuss and make 

recommendations on issues relevant to 

FDA’s reevaluation of the ReGen 

Collagen Scaffold (CS) device (marketed 

as the Menaflex®), which FDA cleared 

in K082079 on December 18, 2008, 

sponsored by ReGen Biologics, Inc. The 

indications for use statement for this 

device states that the device is intended 

for use in surgical procedures for the 

reinforcement and repair of soft tissue 

injuries of the medial meniscus. In 

repairing and reinforcing medial 

meniscal defects, the patient must have 

an intact meniscal rim and anterior and 

posterior horns for attachment of the 

mesh. In addition, the surgically 

prepared site for the CS must extend at 

least into the red/white zone of the 

meniscus to provide sufficient 

vascularization. The CS reinforces soft 

tissue and provides a resorbable scaffold 

that is replaced by the patient’s own soft 

tissue. The CS is not a prosthetic device 

and is not intended to replace normal 

body structure. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present views, orally or in writing, on 

issues pending before the committee. 

These views may be submitted in 

writing to the contact person on or 

before March 16, 2010. Oral 

presentations from the public will be 

scheduled at approximately 1 p.m., 

immediately following lunch. Those 

desiring to make formal oral 

presentations should notify the contact 

person and submit a brief statement of 

the general nature of the arguments they 

wish to present, the names and 

addresses of proposed participants, and 

an indication of the approximate time 

requested to make their presentation on 

or before March 8, 2010. Time allotted 

for each presentation may be limited. If 

the number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by March 9, 2010. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact AnnMarie 

Williams, at 301–796–5966, at least 7 

days in advance of the meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/Advisory

Committees/AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: February 24, 2010. 

Joanne Less, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–4260 Filed 3–1–10; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Impact of 

Japanese Encephalitis Vaccination in 

Cambodia, Funding Opportunity 

Announcement (FOA) CK10–003, Initial 

Review 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the aforementioned meeting: 

Time and Date: 12 p.m.–2 p.m., May 3, 

2010 (Closed). 

Place: Teleconference. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in Section 552b(c)(4) and (6), Title 5 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Matters to be Discussed: The meeting will 

include the initial review, discussion, and 

evaluation of applications received in 

response to ‘‘Impact of Japanese Encephalitis 

Vaccination in Cambodia, FOA CK10–003.’’ 

Contact Person for More Information: 

Gregory Anderson, M.S., M.P.H., Scientific 

Review Officer, CDC, 1600 Clifton Road, NE., 

Mailstop E60, Atlanta, GA 30333, Telephone: 

(404) 498–2293. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both CDC and the Agency for Toxic 

Substances and Disease Registry. 

Dated: February 24, 2010. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2010–4288 Filed 3–1–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HOMELAND 

SECURITY 

U.S. Customs and Border Protection 

Agency Information Collection 

Activities: African Growth and 

Opportunity Act Certificate of Origin 

AGENCY: U.S. Customs and Border 

Protection (CBP), Department of 

Homeland Security. 

ACTION: 60-Day Notice and request for 

comments; Extension of an existing 

collection of information: 1651–0082. 

SUMMARY: As part of its continuing effort 

to reduce paperwork and respondent 

WReier-Aviles on DSKGBLS3C1PROD with NOTICES

9424 Federal Register / Vol. 75, No. 40 / Tuesday, March 2, 2010 / Notices 

burden, CBP invites the general public 

and other Federal agencies to comment 

on an information collection 

requirement concerning the African 

Growth and Opportunity Act Certificate 

of Origin (AGOA). This request for 

comment is being made pursuant to the 

Paperwork Reduction Act of 1995 (Pub. 

L. 104–13; 44 U.S.C. 3505(c)(2)). 

DATES: Written comments should be 

received on or before May 3, 2010, to be 

assured of consideration. 

ADDRESSES: Direct all written comments 

to U.S. Customs and Border Protection, 

Attn: Tracey Denning, Office of 

Regulations and Rulings, 799 9th Street, 

NW., 7th Floor, Washington, DC 20229– 

1177. 

FOR FURTHER INFORMATION CONTACT: 

Requests for additional information 

should be directed to Tracey Denning, 

U.S. Customs and Border Protection, 

Office of Regulations and Rulings, 799 

9th Street, NW., 7th Floor, Washington, 

DC 20229–1177, at 202–325–0265. 

SUPPLEMENTARY INFORMATION: CBP 

invites the general public and other 

Federal agencies to comment on 

proposed and/or continuing information 

collections pursuant to the Paperwork 

Reduction Act of 1995 (Pub. L. 104–13; 

44 U.S.C. 3505(c)(2)). The comments 

should address: (a) Whether the 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimates of the burden of the 

collection of information; (c) ways to 

enhance the quality, utility, and clarity 

of the information to be collected; (d) 

ways to minimize the burden including 

the use of automated collection 

techniques or the use of other forms of 

information technology; and (e) the 

annual costs burden to respondents or 

record keepers from the collection of 

information (a total capital/startup costs 

and operations and maintenance costs). 

The comments that are submitted will 

be summarized and included in the CBP 

request for Office of Management and 

Budget (OMB) approval. All comments 

will become a matter of public record. 

In this document CBP is soliciting 

comments concerning the following 

information collection: 

Title: African Growth and 

Opportunity Act Certificate of Origin. 

OMB Number: 1651–0082. 

Form Number: None. 

Abstract: The information collected is 

used to verify eligibility for duty 

preferences under the provisions of 

AGOA. It is provided for under 19 CFR 

10.214, 10.215, and 10.216. Specifically, 

this program provides duty-free 

treatment under the Generalized System 

of Preferences (GSP) to sensitive articles 

normally excluded from GSP duty 

treatment. It also provides for the entry 

of specific textile and apparel articles 

free of duty and free of any quantitative 

limits from the countries of sub-Saharan 

Africa. 

Current Actions: This submission is 

being made to extend the expiration 

date with a change to the burden hours. 

Type of Review: Extension (with 

change). 

Affected Public: Businesses. 

Estimated Number of Respondents: 

375. 

Estimated Time per Respondent: 20 

minutes. 

Estimated Total Annual Burden 

Hours: 8,925. 

Dated: February 25, 2010. 

Tracey Denning, 

Agency Clearance Officer, U.S. Customs and 

Border Protection. 

[FR Doc. 2010–4287 Filed 3–1–10; 8:45 am] 

BILLING CODE 9111–14–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Internal Agency Docket No. FEMA–3308– 

EM; Docket ID FEMA–2010–0002] 

Oklahoma; Amendment No. 1 to Notice 

of an Emergency Declaration 

AGENCY: Federal Emergency 

Management Agency, DHS. 

ACTION: Notice. 

SUMMARY: This notice amends the notice 

of an emergency declaration for the 

State of Oklahoma (FEMA–3308–EM), 

dated January, 30, 2010, and related 

determinations. 

DATES: Effective Date: January, 30, 2010. 

FOR FURTHER INFORMATION CONTACT: 

Peggy Miller, Disaster Assistance 

Directorate, Federal Emergency 

Management Agency, 500 C Street, SW., 

Washington, DC 20472, (202) 646–3886. 

SUPPLEMENTARY INFORMATION: Notice is 

hereby given that the incident period for 

this emergency is closed effective 

January, 30, 2010. 

The following Catalog of Federal Domestic 

Assistance Numbers (CFDA) are to be used 

for reporting and drawing funds: 97.030, 

Community Disaster Loans; 97.031, Cora 

Brown Fund; 97.032, Crisis Counseling; 

97.033, Disaster Legal Services; 97.034, 

Disaster Unemployment Assistance (DUA); 

97.046, Fire Management Assistance Grant; 

97.048, Disaster Housing Assistance to 

Individuals and Households In Presidentially 

Declared Disaster Areas; 97.049, 

Presidentially Declared Disaster Assistance— 

Disaster Housing Operations for Individuals 

and Households; 97.050, Presidentially 

Declared Disaster Assistance to Individuals 

and Households—Other Needs; 97.036, 

Disaster Grants—Public Assistance 

(Presidentially Declared Disasters); 97.039, 

Hazard Mitigation Grant. 

W. Craig Fugate, 

Administrator, Federal Emergency 

Management Agency. 

[FR Doc. 2010–4223 Filed 3–1–10; 8:45 am] 

BILLING CODE 9111–23–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Internal Agency Docket No. FEMA–1874– 

DR; Docket ID FEMA–2010–0002] 

Virginia; Major Disaster and Related 

Determinations 

AGENCY: Federal Emergency 

Management Agency, DHS. 

ACTION: Notice. 

SUMMARY: This is a notice of the 

Presidential declaration of a major 

disaster for the Commonwealth of 

Virginia (FEMA–1874–DR), dated 

February 16, 2010, and related 

determinations. 

DATES: Effective Date: February 16, 

2010. 

FOR FURTHER INFORMATION CONTACT: 

Peggy Miller, Disaster Assistance 

Directorate, Federal Emergency 

Management Agency, 500 C Street, SW., 

Washington, DC 20472, (202) 646–3886. 

SUPPLEMENTARY INFORMATION: Notice is 

hereby given that, in a letter dated 

February 16, 2010, the President issued 

a major disaster declaration under the 

authority of the Robert T. Stafford 

Disaster Relief and Emergency 

Assistance Act, 42 U.S.C. 5121 et seq. 

(the ‘‘Stafford Act’’), as follows: 

I have determined that the damage in 

certain areas of the Commonwealth of 

Virginia resulting from a severe winter storm 

and snowstorm during the period of 

December 18–20, 2009, is of sufficient 

severity and magnitude to warrant a major 

disaster declaration under the Robert T. 

Stafford Disaster Relief and Emergency 

Assistance Act, 42 U.S.C. 5121 et seq. (the 

‘‘Stafford Act’’). 

Therefore, I declare that such a major 

disaster exists in the Commonwealth of 

Virginia. 

In order to provide Federal assistance, you 

are hereby authorized to allocate from funds 

available for these purposes such amounts as 

you find necessary for Federal disaster 

assistance and administrative expenses. 

WReier-Aviles on DSKGBLS3C1PROD with NOTICES